Medicines for Hodgkin lymphoma: understanding chemotherapy, CD30 treatment, and PD-1 therapy

Seeing ABVD, AVD, BV, and PD-1 on the same treatment page can make a first prescription for Hodgkin lymphoma difficult to understand. The useful starting point is the role of each medicine in the whole plan. A drug used at diagnosis may have a different purpose when it is used after relapse, and evidence for a combination cannot automatically be applied to that drug alone. Ask the prescriber to identify the treatment setting before comparing individual names.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

ABVD contains doxorubicin, bleomycin, vinblastine, and dacarbazine. AVD leaves out bleomycin. Having one fewer drug does not automatically mean that treatment is inadequate. In a defined advanced-stage pathway, the RATHL trial supports a response-adapted decision about bleomycin after an interim PET scan. That evidence does not authorize a patient to remove bleomycin at any point in any regimen.[S5]
Antiemetics, growth factors, and medicines used for particular infection risks may accompany anticancer treatment. Their instructions are not interchangeable. Ask which drugs are scheduled, which are used only if symptoms occur, and whom to contact after a missed or vomited dose. A supportive-care calendar borrowed from a different chemotherapy regimen can be misleading.[S9][S20]
Before starting in China and continuing elsewhere, ask both teams whether they can deliver the intended medicines and monitoring. Brand names, authorized uses, and reimbursement rules may differ. Carry a treatment summary showing generic drug names, actual doses and dates, major reactions, and unresolved problems. “Completed several courses” is not enough information for the next prescriber.[S13]

Quick answer

Full guide

The discussion below concerns classical Hodgkin lymphoma. Nodular lymphocyte-predominant disease has different biological features and may require different medicines. If a hospital in China is reviewing the diagnosis, provide the original pathology material and immunohistochemistry results before treating a preliminary drug list as a final prescription. A reliable treatment decision starts with knowing which disease is being treated.[S2]

Translate the abbreviations on the prescription

ABVD contains doxorubicin, bleomycin, vinblastine, and dacarbazine. AVD leaves out bleomycin. Having one fewer drug does not automatically mean that treatment is inadequate. In a defined advanced-stage pathway, the RATHL trial supports a response-adapted decision about bleomycin after an interim PET scan. That evidence does not authorize a patient to remove bleomycin at any point in any regimen.[S5]

Record generic names as well as brand names. Vinblastine is not interchangeable with another similarly named vinca drug simply because the names look alike. During an international transfer, a description such as “the red infusion” does not establish what was given. The receiving team needs actual doses, dates, and reasons for changes. A pharmacy can then check the prescription against the treatment history instead of reconstructing it from photographs of infusion bags.

Understand what a cycle includes

Combination chemotherapy uses medicines with different actions and different effects on healthy tissue. A cycle can include more than one treatment visit, followed by time for recovery and laboratory monitoring. Some supportive medicines are taken at home. Ask the team to map the prescription to dates so that a family member does not mistake a completed infusion for a completed cycle.[S20]

The number of visible bags is a poor way to compare treatment. Preparation methods, fluids, and supportive medicines can alter what the patient sees. If a drug appears to be missing, ask the nurse or pharmacist to check the signed treatment order. If a name or patient identifier seems wrong, raise it before administration. These questions can be resolved without trying to infer a prescription from another patient's experience.

What brentuximab vedotin does

Brentuximab vedotin, often abbreviated to BV, is an antibody-drug conjugate directed at CD30. The antibody is linked to a cell-killing component. The word targeted therefore does not mean that healthy tissues are unaffected. Peripheral nerve symptoms and changes in blood counts remain relevant, and monitoring is part of using the medicine.[S1][S38]

BV may appear in discussions about initial combination treatment, relapsed disease, or selected post-transplant strategies. These are separate clinical questions with different supporting evidence. Ask which question the proposed prescription addresses. If an overseas publication describes a first-line combination, that does not establish that the same use is authorized or available in China. The Chinese National Health Commission's 2025 guidance distinguishes domestic indications from separately marked material about other settings or jurisdictions.[S7]

PD-1 treatment is a specific form of immunotherapy

PD-1 inhibitors such as nivolumab and pembrolizumab act on an immune checkpoint. They are not general supplements for improving resistance to illness. Patients can still develop infections, and the treatment can also provoke inflammation in healthy organs. Lung, bowel, liver, and endocrine problems require clinical assessment rather than an assumption that any symptom is evidence of a stronger immune system.[S37]

In March 2026, the US FDA approved nivolumab with AVD for previously untreated stage III or IV classical Hodgkin lymphoma in adults and children aged at least 12 years. The age, stage, disease subtype, and combination are all part of that decision. It is a US authorization and does not by itself establish the corresponding Chinese indication or a hospital's ability to deliver it.[S3]

Medicines in the same class cannot simply be swapped

PD-1 medicines have different study populations, labels, and schedules. Chinese guidance lists several agents for classical Hodgkin lymphoma after specified previous treatment. A later-line indication should not be rewritten as a general first-line recommendation. A clinician proposing a particular agent needs to explain the evidence for that agent in the intended setting.[S7]

If the planned medicine is unavailable, changing to another drug requires a new review of the combination, its evidence, and the monitoring arrangements. Buying it independently may create difficulties with verification, storage, hospital acceptance, and recording of adverse effects. Obtain confirmation from the treating hospital about the exact product and supply process. National marketing authorization and stock at a specific hospital on a specific date are separate matters.

Previous exposure matters when disease returns

For relapsed classical Hodgkin lymphoma, the team needs to know whether BV or a PD-1 inhibitor was used before, whether a transplant was performed, how long a response lasted, and which toxicities remain. The size of the present mass does not answer those questions. A medicine may be intended to produce a response before autologous transplantation, or it may be part of a longer disease-control strategy for someone following a different path.[S14]

KEYNOTE-204 compared pembrolizumab with BV in a defined population whose disease had returned after autologous transplantation or who were ineligible for it. It showed a progression-free survival benefit for pembrolizumab in that setting. This is useful evidence, but it does not make one medicine obligatory in every relapse scenario or predict how many months an individual will remain well. Previous therapies and transplant plans still need to be considered.[S26]

Review existing illnesses before the first dose

Tell the team about cardiac or lung disease, hepatitis, existing neuropathy, autoimmune conditions, and any previous organ or stem cell transplant. Bring one list containing prescribed medicines, nonprescription products, herbs, and supplements. Steroids, anticoagulants, and diabetes medicines should not disappear from the history because they were prescribed by a different clinic.[S2]

Do not independently stop a chronic medicine to make the cancer prescription seem simpler. Instead, identify who will coordinate changes. For example, altered food intake can affect diabetes management, while steroids used for a suspected immune complication have a different purpose from routine home treatment. When two teams are involved, written responsibilities reduce the chance that each assumes the other is monitoring a problem.

Include supportive medicines in the conversation

Antiemetics, growth factors, and medicines used for particular infection risks may accompany anticancer treatment. Their instructions are not interchangeable. Ask which drugs are scheduled, which are used only if symptoms occur, and whom to contact after a missed or vomited dose. A supportive-care calendar borrowed from a different chemotherapy regimen can be misleading.[S9][S20]

The FDA's March 2026 nivolumab-AVD information recommends primary G-CSF prophylaxis beginning in the first cycle. This is a detail of that combination that the prescribing team must incorporate into the whole plan. It should not be turned into a universal home injection schedule for every treatment containing AVD. The patient needs the actual prescription and the service responsible for follow-up, especially when injections occur outside the cancer center.[S3]

Describe nerve symptoms in terms of daily function

Tingling in the toes may feel too minor to mention during a busy appointment. It becomes more clinically useful when the patient explains whether it is spreading, whether buttons or handwriting are harder, or whether balance has changed. Such symptoms can influence how BV or a vinca drug is continued. Reporting them early allows assessment before they substantially restrict daily activity.[S38]

A simple dated note is enough. Record when the symptom started, whether it is present between cycles, and what tasks it affects. Avoid diagnosing the cause yourself or taking a high-dose supplement on the assumption that all numbness reflects a vitamin deficiency. The team may need to distinguish treatment toxicity from a pre-existing condition or another cause. If walking is unsafe, tell them promptly and ask about practical support at home.

New breathing or bowel symptoms need assessment

After bleomycin or PD-1 treatment, a new cough or breathlessness cannot be reliably classified at home as infection, drug-related inflammation, or a consequence of lymphoma. Persistent diarrhea, jaundice, or marked weakness can also require urgent review. Follow the team's instructions for contacting the service, and use emergency care for severe symptoms rather than waiting for the next infusion.[S37]

Immune-related effects can arise after the medicine has stopped. Give emergency clinicians the drug name and last treatment date, even if the current problem initially seems unrelated. Keep this information somewhere accessible without the main caregiver's phone. When care is split between countries, a short treatment alert in the local language can help the emergency team recognize a relevant exposure quickly.

A dose change needs an explanation, not a guess

Holding a drug because of toxicity is different from changing treatment because lymphoma has progressed. Neither should be summarized merely as “the plan changed.” Ask for the reason, the replacement or recovery plan, and the next assessment point. This also helps when an insurer or receiving doctor compares the original proposal with what was actually administered.

Do not conceal fever or severe diarrhea to stay on schedule. Equally, one difficult day does not justify stopping every medicine without advice. Decisions about delay, dose reduction, or omission require the clinical team to weigh treatment benefit against the current risk. Save each revised treatment sheet. A proposed dose that was never given should not be counted as prior exposure during a later consultation.

Discuss fertility before exposure where possible

The effects on ovarian or testicular function differ among regimens and depend on age and previous treatment. Anyone who may want future biological children can ask about sperm, egg, or embryo preservation before starting. Having regular periods or apparently normal sexual function does not establish that fertility is unaffected.[S10][S11]

The time available for preservation must be discussed with the hematology and reproductive teams. Requirements for contraception and advice about attempting pregnancy also depend on the actual medicines and recovery. Do not apply a waiting period found for one chemotherapy drug to every immune or targeted treatment. If pregnancy is possible during treatment, tell the team promptly so that an individual assessment can be arranged.

Ask for a usable medicine quotation in China

A cost inquiry should identify the proposed regimen and previous treatment, with weight or other information supplied when the hospital requests it. The hospital must confirm the final dose. Request separate RMB entries for drugs, administration, laboratory monitoring, supportive treatment, and any expected inpatient care. Where relevant, ask how whole vials and unused portions are charged. No verified patient-specific quotation is available in this article.[S12]

If a figure is still unknown, label it as awaiting confirmation. A single advertised total can obscure assumptions about cycles or complications. Ask what happens financially if a drug is held or changed, and whether the quote remains valid at the intended treatment date. These questions help a family compare actual proposals without inventing a price range that may not apply to its prescription.

Prepare for care across two countries

Before starting in China and continuing elsewhere, ask both teams whether they can deliver the intended medicines and monitoring. Brand names, authorized uses, and reimbursement rules may differ. Carry a treatment summary showing generic drug names, actual doses and dates, major reactions, and unresolved problems. “Completed several courses” is not enough information for the next prescriber.[S13]

At the end of a drug consultation, try to leave with a clear answer about the exact combination, why it fits the current treatment stage, and which assessment will guide the next decision. A caregiver can help take notes, but the patient should retain the same information. At follow-up, report medicines added outside the cancer clinic as well as any treatment that was missed or stopped. An accurate record makes the next discussion about new drugs more relevant to the person's actual care.